dukiprubart (SGC001)
/ Beijing Sungen Biomedical Technology, Hotgen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
September 05, 2026
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
(clinicaltrials.gov)
- P2 | N=129 | Not yet recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P2 trial • Pancreatitis
September 05, 2026
Safety, Tolerability, Pharmacokinetics, and Efficacy of SGC001 in Chinese Patients with Acute STEMI: A Phase Ib Dose-Escalation Study
(AHA 2026)
- "Abstract is embargoed at this time."
Clinical • P1 data • PK/PD data • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease
July 14, 2026
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
(clinicaltrials.gov)
- P2 | N=210 | Recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Trial completion date: Jun 2027 ➔ Oct 2027
Trial completion date • Cardiovascular • Myocardial Infarction
May 20, 2026
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
(clinicaltrials.gov)
- P2 | N=210 | Recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Myocardial Infarction
January 31, 2026
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Pharmacodynamics Profile and Immunogenicity of SGC001 in Healthy Adult Subjects
(ChiCTR)
- P1 | N=48 | Completed | Sponsor: Beijing Anzhen Hospital Capital Medical University; Beijing Sungen Biomedical Technology Co., Ltd.
New P1 trial • Cardiovascular • Myocardial Infarction
December 30, 2025
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
(clinicaltrials.gov)
- P2 | N=210 | Not yet recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P2 trial • Cardiovascular • Myocardial Infarction
November 26, 2025
A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=49 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Myocardial Infarction
November 26, 2025
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
(clinicaltrials.gov)
- P1 | N=38 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Nov 2025 ➔ Jul 2025
Trial completion • Trial completion date • Cardiovascular • Myocardial Infarction
July 30, 2025
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
(clinicaltrials.gov)
- P1 | N=33 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P1 trial • Cardiovascular • Myocardial Infarction
July 25, 2025
A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
New P1 trial • Cardiovascular • Myocardial Infarction
1 to 10
Of
10
Go to page
1